IL108111A - Phosphonoxymethyl Texan History Sites, Preparation and Pharmaceutical Preparations Containing Them - Google Patents

Phosphonoxymethyl Texan History Sites, Preparation and Pharmaceutical Preparations Containing Them

Info

Publication number
IL108111A
IL108111A IL10811193A IL10811193A IL108111A IL 108111 A IL108111 A IL 108111A IL 10811193 A IL10811193 A IL 10811193A IL 10811193 A IL10811193 A IL 10811193A IL 108111 A IL108111 A IL 108111A
Authority
IL
Israel
Prior art keywords
compound
hydroxy
hydrogen
formula
mmol
Prior art date
Application number
IL10811193A
Other languages
English (en)
Hebrew (he)
Other versions
IL108111A0 (en
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL108111A0 publication Critical patent/IL108111A0/xx
Publication of IL108111A publication Critical patent/IL108111A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer
    • H01L21/48—Manufacture or treatment of parts, e.g. containers, prior to assembly of the devices, using processes not provided for in a single one of the subgroups H01L21/06 - H01L21/326
    • H01L21/4814—Conductive parts
    • H01L21/4821—Flat leads, e.g. lead frames with or without insulating supports
    • H01L21/4839—Assembly of a flat lead with an insulating support, e.g. for TAB

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Computer Hardware Design (AREA)
  • Power Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
IL10811193A 1992-12-24 1993-12-21 Phosphonoxymethyl Texan History Sites, Preparation and Pharmaceutical Preparations Containing Them IL108111A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99645592A 1992-12-24 1992-12-24
US10801593A 1993-08-17 1993-08-17
US15484093A 1993-11-24 1993-11-24

Publications (2)

Publication Number Publication Date
IL108111A0 IL108111A0 (en) 1994-04-12
IL108111A true IL108111A (en) 2002-09-12

Family

ID=27380404

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10811193A IL108111A (en) 1992-12-24 1993-12-21 Phosphonoxymethyl Texan History Sites, Preparation and Pharmaceutical Preparations Containing Them

Country Status (21)

Country Link
EP (1) EP0604910B1 (de)
JP (1) JP3189140B2 (de)
KR (2) KR100241852B1 (de)
CN (2) CN1037774C (de)
AT (1) ATE193891T1 (de)
AU (1) AU660570B2 (de)
CA (1) CA2111527C (de)
CZ (1) CZ289871B6 (de)
DE (1) DE69328858T2 (de)
DK (1) DK0604910T3 (de)
ES (1) ES2147739T3 (de)
FI (1) FI111724B (de)
GR (1) GR3034312T3 (de)
HU (1) HUT65547A (de)
IL (1) IL108111A (de)
MX (1) MX9308012A (de)
NO (1) NO310238B1 (de)
NZ (1) NZ250550A (de)
PL (1) PL175014B1 (de)
PT (1) PT604910E (de)
TW (1) TW410228B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329304T2 (de) * 1992-01-15 2001-01-04 Squibb & Sons Inc Enzymatische Verfahren zur Resolution von Enantiomeren-Mischungen nützlich wie Zwischenprodukte zur Herstellung von Taxanen
WO1994010997A1 (en) * 1992-11-13 1994-05-26 Florida State University Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
CA2119261C (en) * 1992-12-23 2006-01-31 Michael A. Poss Novel sidechain-bearing taxanes and intermediates thereof
US6593482B2 (en) * 1993-02-01 2003-07-15 Aventis Pharma S.A. Methods for preparing new taxoids and pharmaceutical compositions containing them
TW397866B (en) 1993-07-14 2000-07-11 Bristol Myers Squibb Co Enzymatic processes for the resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
CA2129288C (en) * 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
FR2712289B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5677470A (en) * 1994-06-28 1997-10-14 Tanabe Seiyaku Co., Ltd. Baccatin derivatives and processes for preparing the same
US6201140B1 (en) 1994-07-28 2001-03-13 Bristol-Myers Squibb Company 7-0-ethers of taxane derivatives
AU4133096A (en) * 1994-10-28 1996-05-23 Research Foundation Of The State University Of New York, The Taxoid derivatives, their preparation and their use as antitumor agents
US6500858B2 (en) 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6458976B1 (en) 1994-10-28 2002-10-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods
CA2162759A1 (en) * 1994-11-17 1996-05-18 Kenji Tsujihara Baccatin derivatives and processes for preparing the same
US5489589A (en) * 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
IT1275936B1 (it) * 1995-03-17 1997-10-24 Indena Spa Derivati della 10-deacetilbaccatina iii e della 10-deacetil-14b- idrossibaccatina iii loro metodo di preparazione e formulazioni
US5847170A (en) * 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
US5840929A (en) * 1995-04-14 1998-11-24 Bristol-Myers Squibb Company C4 methoxy ether derivatives of paclitaxel
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
JP3737518B2 (ja) 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー， エル．ピー． 水溶性パクリタキセルプロドラッグ
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5635531A (en) * 1996-07-08 1997-06-03 Bristol-Myers Squibb Company 3'-aminocarbonyloxy paclitaxels
US5977386A (en) * 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US5902822A (en) * 1997-02-28 1999-05-11 Bristol-Myers Squibb Company 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels
US6156789A (en) * 1998-03-17 2000-12-05 Rhone-Poulenc Rorer S.A. Method for treating abnormal cell proliferation in the brain
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6780879B2 (en) 2000-02-02 2004-08-24 Fsu Research Foundation, Inc. C7 carbonate substituted taxanes
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
CN1186340C (zh) 2000-02-02 2005-01-26 佛罗里达州立大学研究基金有限公司 用作抗肿瘤剂的c10碳酸酯取代的紫杉烷
US20020077290A1 (en) 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
MXPA03002494A (es) 2000-09-22 2004-05-24 Bristol Myers Squibb Co Metodo para reducir toxicidad de quimio terapias combinadas.
AU2001290636A1 (en) * 2000-09-22 2002-04-02 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
WO2003047508A2 (en) 2001-11-30 2003-06-12 Bristol-Myers Squibb Company Paclitaxel solvates
US7834043B2 (en) 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
PE20050693A1 (es) 2004-02-13 2005-09-27 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
EP2336138A3 (de) * 2004-07-06 2011-11-16 Abbott Laboratories Prodrugs von hiv-protease inhibitoren
EP2080764B1 (de) 2008-01-18 2012-08-22 INDENA S.p.A. Feste Formen von Ortataxel
CA2718567A1 (en) 2008-03-31 2009-12-03 Florida State University Research Foundation, Inc. C(10) ethyl ester and c(10) cyclopropyl ester substituted taxanes
CN101648973B (zh) * 2009-09-03 2012-05-30 漆又毛 水溶性紫杉烷及制备方法
CA2846572C (en) 2011-08-25 2019-12-31 Bonac Corporation Glycoside compounds, method for producing the compounds, and production of nucleic acids using said compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
CA2129288C (en) * 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives

Also Published As

Publication number Publication date
PT604910E (pt) 2000-09-29
AU5260993A (en) 1994-07-07
KR940014375A (ko) 1994-07-18
NO934614L (no) 1994-06-27
CA2111527C (en) 2000-07-18
IL108111A0 (en) 1994-04-12
GR3034312T3 (en) 2000-12-29
EP0604910B1 (de) 2000-06-14
FI935821A0 (fi) 1993-12-23
CN1184219C (zh) 2005-01-12
MX9308012A (es) 1994-08-31
CN1174838A (zh) 1998-03-04
JPH072885A (ja) 1995-01-06
DE69328858D1 (de) 2000-07-20
NZ250550A (en) 1995-02-24
EP0604910A1 (de) 1994-07-06
ES2147739T3 (es) 2000-10-01
NO934614D0 (no) 1993-12-15
PL301610A1 (en) 1994-06-27
HUT65547A (en) 1994-06-28
NO310238B1 (no) 2001-06-11
DE69328858T2 (de) 2001-03-01
CN1037774C (zh) 1998-03-18
CZ289871B6 (cs) 2002-04-17
JP3189140B2 (ja) 2001-07-16
DK0604910T3 (da) 2000-07-31
FI935821A (fi) 1994-06-25
AU660570B2 (en) 1995-06-29
TW410228B (en) 2000-11-01
KR100241852B1 (ko) 2000-03-02
KR100274373B1 (en) 2000-12-15
FI111724B (fi) 2003-09-15
CZ285593A3 (en) 1994-12-15
ATE193891T1 (de) 2000-06-15
CA2111527A1 (en) 1994-06-25
CN1093369A (zh) 1994-10-12
PL175014B1 (pl) 1998-10-30

Similar Documents

Publication Publication Date Title
EP0604910B1 (de) Phosphonooxymethylether von Taxan-Derivaten
EP0639577B1 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
US6455575B2 (en) Phosphonooxymethyl ethers of taxane derivatives
EP0590267B1 (de) Desoxy-Taxol-Derivate
FI109795B (fi) Menetelmä terapeuttisesti käyttökelpoisten 6,7-modifioitujen paklitakseleiden valmistamiseksi
US5478854A (en) Deoxy taxols
EP0694539B1 (de) 7-O-Ether von Taxanderivaten
IL118526A (en) History of paclitaxel and precursors containing them
WO1997046232A1 (en) 7-deoxy-6-substituted paclitaxels
NZ248017A (en) 7-fluoro-taxol derivatives, precursors and pharmaceutical compositions thereof
RU2136673C1 (ru) Фосфонооксиметиловые эфиры таксановых производных, промежуточные соединения, противоопухолевая фармацевтическая композиция, способ ингибирования роста опухоли у млекопитающих

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees